Anavex Life Sciences Corp (AVXL)

[Investor2014]

Not if EMA doesn't find the P2b/3 trial as sufficient for full approval. This because a P4 trial is generally open label and paid by patients, as its purposed is to underpin an accelerated/ conditional approval in terms of log term safety and efficacy. Anavex have applied for full approval, so their data has stack up as pivotal for that.